Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Citius Pharmaceuticals, Inc. on February 9, 2026. The filing addresses two primary events: the issuance of a press release regarding the first quarter of fiscal 2026 results of operations and a formal notice from Nasdaq regarding the Company's failure to meet the minimum bid price requirement for continued listing.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the results of operations for the first quarter of fiscal 2026. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these financial metrics.
Material Changes and Listing Status
The most significant material event reported is the Company's receipt of a notice from Nasdaq Stock Market LLC on February 9, 2026. The notice states that for the last 30 consecutive business days, the bid price for the Company's common stock closed below the $1.00 per share minimum required by Nasdaq Listing Rule 5550(a)(2).
- Compliance Period: The Company has 180 calendar days, until August 10, 2026, to regain compliance.
- Compliance Requirement: The bid price must close at $1.00 per share or more for a minimum of ten consecutive business days.
- Delisting Risk: Failure to regain compliance by the deadline may result in delisting, though the Company may be eligible for an additional 180-day period if it meets other listing standards and effects a reverse stock split.
Outlook, Risks, and Management Commentary
Management is currently evaluating options to regain compliance with the Bid Price Rule. The filing explicitly states there can be no assurance that the Company will regain compliance or maintain other Nasdaq continued listing requirements. The notice has no immediate effect on the listing, and the stock will continue to trade under the symbol "CTXR" on the Nasdaq Capital Market.
Key Facts for Investor Verification
- Verify the specific financial results for Q1 Fiscal 2026 by reviewing the press release attached as Exhibit 99.1, as this 8-K does not contain the data.
- Monitor the daily closing bid price of CTXR stock to track progress toward the $1.00 threshold required for Nasdaq compliance.
- Watch for announcements regarding a potential reverse stock split, which may be necessary to regain compliance if the market price does not recover naturally.
- Confirm the Company's cash position and liquidity status in the referenced press release to assess its ability to fund operations while addressing the listing deficiency.